ANTI-IL2 GAMMA RECEPTOR ANTIGEN-BINDING PROTEINS

MX434842BActive Publication Date: 2026-06-12REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
MX · MX
Patent Type
Patents
Current Assignee / Owner
REGENERON PHARMACEUTICALS INC
Filing Date
2021-07-23
Publication Date
2026-06-12

AI Technical Summary

Technical Problem

Current treatments for diseases mediated by the IL-2 receptor gamma (IL2Ry) chain, such as graft-versus-host disease and autoimmune disorders, lack effective therapies that specifically target IL2Ry signaling pathways without broad immunosuppression.

Method used

Development of antigen-binding proteins, including antibodies and fragments, that specifically bind to human and Macaca fascicularis IL2Ry with high affinity, blocking cytokine-induced STAT phosphorylation and reducing immune cell counts, thereby modulating IL2Ry-mediated immune responses.

Benefits of technology

These antigen-binding proteins effectively block IL2Ry signaling, reducing immune cell numbers and cytokine levels, thereby providing therapeutic benefits in IL2Ry-mediated diseases without broad immunosuppression.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that specifically bind to the human IL2 gamma receptor (IL2R). Methods for treating or preventing IL2R-mediated diseases (e.g., graft-versus-host disease) using the antibodies and fragments, along with methods for manufacturing the antibodies and fragments, are also provided.
Need to check novelty before this filing date? Find Prior Art